Boehringer Ingelheim's 'Jascayd (nerandomilast)' Receives Final Approval in Europe as a Treatment for Idiopathic Pulmonary Fibrosis
European Commission Grants Final Approval for Jascayd
The European Commission (EC) has granted final approval for Jascayd (nerandomilast), Boehringer Ingelheim's treatment for idiopathic pulmonary fibrosis (IPF). This approval, applicable to adult patients with IPF and progressive fibrosing interstitial lung diseases (PF-ILD), follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) in May 2026, and was officially completed on July 17, 2026. This follows the FDA's approval in October and December 2025 for IPF and PF-ILD indications, respectively. With this approval, Jascayd becomes an innovative new drug available to patients across the European Union (EU) after approximately 10 years.
Differentiated Mechanism of Action as a Selective PDE4B Inhibitor and Clinical Data
Jascayd is a first-in-class selective PDE4B inhibitor that targets inflammation and fibrosis in the lungs. It is designed to selectively block the 4B isoform to overcome the severe gastrointestinal side effects associated with existing non-selective PDE4 inhibitors. In the Phase 3 FIBRONEER-IPF trial, the 18mg group demonstrated significant clinical data, improving FVC decline by 67.2mL (p<0.001) compared to placebo at week 52. The FIBRONEER-ILD trial in PF-ILD patients also showed that both the 9mg and 18mg groups demonstrated significant improvements in lung function compared to placebo, confirming excellent tolerability and efficacy.
Reshaping the Global Market Landscape and Commercial Sales Forecasts
The global market for IPF treatments is estimated at $4.5 to $5.5 billion annually and is projected to expand to approximately $7 billion by the mid-2030s. With Ofev and Esbriet facing patent expiration and generic competition, Jascayd is positioned as a premium new drug that can quickly capture market share. Industry analysts predict that Jascayd will generate global annual sales of at least $380 million in its first year. Until competing drugs such as deupirfenidone (LYT-100) from Celea Therapeutics enter Phase 3 trials, Jascayd is expected to maintain a strong market leadership position.
European Pricing Negotiations and Respiratory Marketing Strategy
To ensure successful market penetration in Europe, it is essential to implement rapid health insurance listing and pricing negotiation strategies tailored to each country's healthcare system. Boehringer Ingelheim plans to actively leverage its existing large hospital sales network and global distribution logistics for its leading respiratory product, Ofev. By demonstrating the patient quality of life improvements and cost-effectiveness data observed in clinical trials, the company aims to overcome the stringent economic evaluation barriers in each European country. A differentiated academic marketing campaign targeting local respiratory specialists is expected to be a key driver of rapid initial prescription uptake.
The European approval of Jascayd (nerandomilast) represents a key milestone in solidifying Boehringer Ingelheim's leading position in the approximately $5 billion global IPF treatment market. The drug demonstrated a 67.2mL (p<0.001) reduction in FVC decline compared to placebo in the Phase 3 (FIBRONEER) trial, along with a superior gastrointestinal tolerability profile, providing a strong competitive advantage over existing standard-of-care treatments such as Ofev (nintedanib) and Esbriet (pirfenidone). With Ofev facing patent expiration and generic entry, this new drug is expected to fill the revenue gap in Boehringer Ingelheim's respiratory portfolio and drive initial global sales of approximately $380 million annually. This will create a high barrier to entry for competing drugs, such as deupirfenidone (LYT-100) from Celea Therapeutics, which is initiating Phase 3 (SURPASS-IPF) trials. In the long term, as country-specific insurance pricing negotiations are completed, market penetration is expected to increase, leading to stable cash flow generation and investment returns.
Source: EMA (ema)